Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide Study
Purpose: Androgen signaling is associated with various secondary cancer, which could be promising for potential treatment using androgen deprivation therapy (ADT). This study investigated whether ADT use was associated with secondary cancers other than prostate cancer in a nationwide population-ba...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Society for Sexual Medicine and Andrology
2025-01-01
|
| Series: | The World Journal of Men's Health |
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841561265901666304 |
|---|---|
| author | Jae Heon Kim Gi Hwan Bae Jaehun Jung Tae Il Noh |
| author_facet | Jae Heon Kim Gi Hwan Bae Jaehun Jung Tae Il Noh |
| author_sort | Jae Heon Kim |
| collection | DOAJ |
| description | Purpose: Androgen signaling is associated with various secondary cancer, which could be promising for potential treatment
using androgen deprivation therapy (ADT). This study investigated whether ADT use was associated with secondary cancers
other than prostate cancer in a nationwide population-based cohort.
Materials and Methods: A total, 278,434 men with newly diagnosed prostate cancer between January 1, 2002 and December
31, 2017 were identified. After applying the exclusion criteria, 170,416 men were enrolled. The study cohort was divided
into ADT and non-ADT groups by individual matching followed by propensity score matching (PSM). Study outcomes were
incidence of all male cancers. Cox proportional hazard regression models were used to estimate adjusted hazard ratios (HRs)
and 95% confidence intervals (CIs) of events.
Results: During a median follow-up of 4.5 years, a total of 11,059 deaths (6,329 in the ADT group and 4,730 in the non-
ADT group) after PSM were found. After PSM, the overall all-cause of secondary cancer incidence risk of the ADT group was
higher than that of the non-ADT group (HR: 1.312, 95% CI: 1.23–1.36; adjusted HR: 1.344, 95% CI: 1.29–1.40). The ADT
group showed higher risk of overall brain and other central nervous system (CNS) cancer-specific incidence than the non-
ADT group (adjusted HR: 1.648, 95% CI: 1.21–2.24). The ADT group showed lower risks of overall cancer-specific incidence
for stomach, colon/rectum, liver/inflammatory bowel disease (IBD), gall bladder/extrahepatic bile duct, lung, bladder, and
kidney cancers than the non-ADT group. When the duration of ADT was more than 2 years of ADT, the ADT group showed
higher risk of cancer-specific incidence for brain and other CNS cancers but lower risk of cancer-specific incidence for liver/
IBD and lung cancers than the non-ADT group.
Conclusions: This study demonstrates that ADT could affect cancer-specific incidence for various cancers. |
| format | Article |
| id | doaj-art-6ea7e73f48654782a2b6d7e5bb52cdd6 |
| institution | Kabale University |
| issn | 2287-4208 2287-4690 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Korean Society for Sexual Medicine and Andrology |
| record_format | Article |
| series | The World Journal of Men's Health |
| spelling | doaj-art-6ea7e73f48654782a2b6d7e5bb52cdd62025-01-03T03:08:13ZengKorean Society for Sexual Medicine and AndrologyThe World Journal of Men's Health2287-42082287-46902025-01-0143112313310.5534/wjmh.230237Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide StudyJae Heon Kim0https://orcid.org/0000-0002-4490-3610Gi Hwan Bae1https://orcid.org/0000-0002-8736-3386Jaehun Jung2https://orcid.org/0000-0002-4856-3668Tae Il Noh3https://orcid.org/0000-0002-5278-7672Department of Urology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, SeoulArtificial Intelligence and Big-Data Convergence Center, Gil Medical Center, Gachon University College of Medicine, IncheonArtificial Intelligence and Big-Data Convergence Center, Gil Medical Center, Gachon University College of Medicine, IncheonDepartment of Urology, Korea University Anam Hospital, Korea University College of Medicine, SeoulPurpose: Androgen signaling is associated with various secondary cancer, which could be promising for potential treatment using androgen deprivation therapy (ADT). This study investigated whether ADT use was associated with secondary cancers other than prostate cancer in a nationwide population-based cohort. Materials and Methods: A total, 278,434 men with newly diagnosed prostate cancer between January 1, 2002 and December 31, 2017 were identified. After applying the exclusion criteria, 170,416 men were enrolled. The study cohort was divided into ADT and non-ADT groups by individual matching followed by propensity score matching (PSM). Study outcomes were incidence of all male cancers. Cox proportional hazard regression models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of events. Results: During a median follow-up of 4.5 years, a total of 11,059 deaths (6,329 in the ADT group and 4,730 in the non- ADT group) after PSM were found. After PSM, the overall all-cause of secondary cancer incidence risk of the ADT group was higher than that of the non-ADT group (HR: 1.312, 95% CI: 1.23–1.36; adjusted HR: 1.344, 95% CI: 1.29–1.40). The ADT group showed higher risk of overall brain and other central nervous system (CNS) cancer-specific incidence than the non- ADT group (adjusted HR: 1.648, 95% CI: 1.21–2.24). The ADT group showed lower risks of overall cancer-specific incidence for stomach, colon/rectum, liver/inflammatory bowel disease (IBD), gall bladder/extrahepatic bile duct, lung, bladder, and kidney cancers than the non-ADT group. When the duration of ADT was more than 2 years of ADT, the ADT group showed higher risk of cancer-specific incidence for brain and other CNS cancers but lower risk of cancer-specific incidence for liver/ IBD and lung cancers than the non-ADT group. Conclusions: This study demonstrates that ADT could affect cancer-specific incidence for various cancers.cohort studiesprostatic neoplasmsreceptors; androgensurvival analysis |
| spellingShingle | Jae Heon Kim Gi Hwan Bae Jaehun Jung Tae Il Noh Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide Study The World Journal of Men's Health cohort studies prostatic neoplasms receptors; androgen survival analysis |
| title | Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide Study |
| title_full | Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide Study |
| title_fullStr | Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide Study |
| title_full_unstemmed | Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide Study |
| title_short | Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide Study |
| title_sort | secondary cancer after androgen deprivation therapy in prostate cancer a nationwide study |
| topic | cohort studies prostatic neoplasms receptors; androgen survival analysis |
| work_keys_str_mv | AT jaeheonkim secondarycancerafterandrogendeprivationtherapyinprostatecanceranationwidestudy AT gihwanbae secondarycancerafterandrogendeprivationtherapyinprostatecanceranationwidestudy AT jaehunjung secondarycancerafterandrogendeprivationtherapyinprostatecanceranationwidestudy AT taeilnoh secondarycancerafterandrogendeprivationtherapyinprostatecanceranationwidestudy |